David Mishkin, DO
Family Medicine · Fort Lauderdale, FLNPI 1700896206
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Viz.ai, Inc. at 57.7% of the total. Reporting peaked in 2022 at $14,710 and has fallen 94.6% since, to $791 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $71.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viz.ai, Inc.$14K
- Meridian Bioscience Inc.$4K
- AbbVie$871
- AstraZeneca$858
- Novo Nordisk$684
- GSK$596
- plus $3K from 35 others
Across 257 payments — averaging $16,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.7M
- Novartis$293K
- BD$82K
- AstraZeneca$79K
- AbbVie$63K
- Amgen$26K
- plus $60K from 6 others
What the payments were for
- Consulting fees$13,73158%
- Food & beverage$6,32627%
- Education$3,75716%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Viz.AI LVO$13,731
How this compares
$23,814 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $221,786 |
| MounjaroTirzepatide | 39 | $41,299 |
| FarxigaDapagliflozin Propanediol | 41 | $37,461 |
| XareltoRivaroxaban | 28 | $34,795 |
| JardianceEmpagliflozin | 26 | $26,058 |
| OzempicSemaglutide | 27 | $24,854 |
| ProliaDenosumab | 14 | $24,746 |
| JanuviaSitagliptin Phosphate | 15 | $24,497 |
| SymbicortBudesonide/Formoterol Fumarate | 79 | $22,520 |
| TrulicityDulaglutide | 13 | $19,825 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $15,712 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,685 |
| QuliptaAtogepant | 13 | $14,284 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $13,079 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $12,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $552 | $221,786195 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $858 | $72,456136 claims |
| Lilly USA, LLCMounjaro, Trulicity | $392 | $61,12452 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $25 | $41,55753 claims |
| Johnson & JohnsonXarelto | $101 | $34,79528 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $596 | $30,39748 claims |
| Novo NordiskOzempic | $684 | $24,85427 claims |
| AmgenProlia | $197 | $24,74614 claims |
| MerckJanuvia | $77 | $24,49715 claims |
| AbbVieQulipta | $871 | $14,28413 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $11,29817 claims |
| Sanofi-aventis U.S. LLCLantus | $16 | $5,38816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fort Lauderdale
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.